(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 2.68% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 2.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.35%.
Novartis Ag's revenue in 2023 is $52,263,000,000.On average, 2 Wall Street analysts forecast NVS's revenue for 2023 to be $116,223,393,605,000, with the lowest NVS revenue forecast at $114,254,273,210,000, and the highest NVS revenue forecast at $118,192,514,000,000. On average, 2 Wall Street analysts forecast NVS's revenue for 2024 to be $117,618,193,990,000, with the lowest NVS revenue forecast at $114,428,304,980,000, and the highest NVS revenue forecast at $120,808,083,000,000.
In 2025, NVS is forecast to generate $124,067,251,000,000 in revenue, with the lowest revenue forecast at $124,067,251,000,000 and the highest revenue forecast at $124,067,251,000,000.